Table 4.

Effects of pyriplatin in combination with various anticancer agents in HT29 and OVCAR-3 cancer cell lines

Cell lineSchedulePaclitaxelGemcitabineSN38Cisplatin5-FU
HT29A0.87 (0.75–0.98)1.66 (0.70–2.76)0.90 (0.72–1.22)1.11 (0.89–1.23)0.94 (0.80–1.03)
B0.88 (0.69–1.22)1.09 (0.89–1.38)2.21 (1.42–3.31)0.96 (0.94–1.22)ND
C0.96 (0.55–1.21)0.86 (0.45–1.49)0.81 (0.62–1.34)0.84 (0.83–0.85)1.02 (0.87–1.20)
OVCAR-3A0.89 (0.63–0.99)1.13 (0.69–1.91)1.08 (1.51–0.77)1.09 (0.96–1.19)0.99 (0.89–1.22)
B1.06 (0.63–1.55)1.31 (0.60–7.22)0.95 (0.94–0.97)0.84 (0.72–1.10)ND
C1.19 (0.87–1.38)1.21 (1.11–1.44)1.38 (1.07–1.99)0.79 (0.74–0.85)1.32 (1.22–1.55)

NOTE: Data are presented as the median combination index value and the 95% confidence interval. Schedule A, 24-hour pyriplatin followed by the 24-hour combination drug; Schedule B, 24-hour combination drug followed by the 24-hour pyriplatin; Schedule C, 24-hour simultaneous exposure.

Abbreviation: ND, not determined.